|
|
Blood, 1 May 2008, Vol. 111, No. 9, pp. 4809-4812.
Prepublished online as a Blood First Edition Paper on December 26, 2007; DOI 10.1182/blood-2007-05-090308.
Previous Article | Next Article 
Submitted May 14, 2007
Accepted November 9, 2007
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia
Zhifu Xiang, Yu Zhao, Vesselin Mitaksov, Daved H Fremont, Yumi Kasai, AnnaLynn Molitoris, Rhonda E Ries, Tracie L Miner, Michael D McLellan, John F DiPersio, Daniel C Link, Jacqueline E Payton, Timothy A Graubert, Mark Watson, William Shannon, Sharon E Heath, Rakesh Naggarajan, Elaine R Mardis, Richard K Wilson, Timothy J Ley, and Michael H Tomasson*
Department of Medicine, Washington University School of Medicine, Saint Louis, MO, United States
Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO, United States
Genome Sequencing Center, Washington University School of Medicine, Saint Louis, MO, United States
Division of Biostatistics, Washington University School of Medicine, Saint Louis, MO, United States
Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, United States
Department of Genetics, Washington University School of Medicine, Saint Louis, MO, United States
* Corresponding author; email: tomasson{at}wustl.edu.
Somatic mutations in JAK2 are frequently found in myeloproliferative diseases, and gain-of-function JAK3 alleles have been identified in M7 acute myeloid leukemia (AML), but a role for JAK1 in AML has not been described. We screened the entire coding region of JAK1 by total exonic re-sequencing of bone marrow DNA samples from 94 patients with de novo AML. We identified two novel somatic mutations in highly conserved residues of the JAK1 gene (T478S, V623A), in two separate patients and confirmed these by re-sequencing germline DNA samples from the same patients. Overexpression of mutant JAK1 did not transform primary murine cells in standard assays, but compared to wild-type JAK1, JAK1T478S and JAK1V623A expression was associated with increased STAT1 activation in response to type I interferon and activation of multiple downstream signaling pathways. This is the first report to demonstrate somatic JAK1 mutations in AML and suggests that JAK1 mutations may function as disease modifying mutations in AML pathogenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Hitchhikers' guide to the leukemia genome
- Nicholas C. P. Cross
Blood 2008 111: 4428-4429.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. H. Tomasson, Z. Xiang, R. Walgren, Y. Zhao, Y. Kasai, T. Miner, R. E. Ries, O. Lubman, D. H. Fremont, M. D. McLellan, et al.
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Blood,
May 1, 2008;
111(9):
4797 - 4808.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |